electroCore, Inc. (ECOR) News

electroCore, Inc. (ECOR): $6.11

0.34 (+5.89%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add ECOR to Watchlist
Sign Up

Filter ECOR News Items

ECOR News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ECOR News Highlights

  • For ECOR, its 30 day story count is now at 3.
  • Over the past 14 days, the trend for ECOR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • DEC are the most mentioned tickers in articles about ECOR.

Latest ECOR News From Around the Web

Below are the latest news stories about ELECTROCORE INC that investors may wish to consider to help them evaluate ECOR as an investment opportunity.

electroCore Expands Intellectual Property Portfolio

electroCore Granted Two New U.S. PatentsROCKAWAY, N.J., Dec. 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trademark Office (USPTO). The two patents were issued on December 26, 2023, and relate to electroCore’s non-invasive vagus nerve stimulation (nVNS) technology: US Patent No. 11,850,056 entitled “Devices and Methods

Yahoo | December 26, 2023

These Stocks under $10 Are Poised To Explode

In this piece, we will take a look at these stocks under $10 are poised to explode. If you want to skip our introduction to these tricky stocks, jump to These 5 Stocks Under $10 Are Poised To Explode. The US equity markets remain on track for a strong finish in 2023 as major indices […]

Yahoo | December 21, 2023

electroCore Expands Intellectual Property Portfolio for Nerve Stimulation Technology

ROCKAWAY, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to a system for stimulating a nerve target in the head or neck of a patient for treatment of various disorders, such as primary headache. U.S. Patent No. 11,839,764 entitled “Systems and Methods for Treating a Medical Condition with an Electrical Stimulation Tre

Yahoo | December 12, 2023

Dr. Peter Staats to Host Analyst Day on the Science Behind gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) on Tuesday, November 21, 2023

ROCKAWAY, N.J., Nov. 15, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company’s Chief Medical Officer, Dr. Peter Staats will host an analyst day entitled “Accessing the Power of Vagus Nerve Stimulation with gammaCore™” on November 21, 2023 at 1:30pm EST. The webinar will cover the nVNS mechanism of action and potential pipeline of indications using the company’s proprietary nVNS technology plat

Yahoo | November 15, 2023

electroCore, Inc. (NASDAQ:ECOR) Q3 2023 Earnings Call Transcript

electroCore, Inc. (NASDAQ:ECOR) Q3 2023 Earnings Call Transcript November 8, 2023 electroCore, Inc. misses on earnings expectations. Reported EPS is $-0.68 EPS, expectations were $-0.64. Operator: Greetings, and welcome to the electroCore Third Quarter 2023 Earnings Conference Call. At this time, all participants on a listen only mode. Please make sure to mute yourself. A […]

Yahoo | November 9, 2023

electroCore Inc (ECOR) Reports Substantial Sales Growth in Q3 2023

Net Sales Surge by 128% Year-Over-Year; Company Raises Full-Year Revenue Guidance

Yahoo | November 8, 2023

electroCore Announces Third Quarter 2023 Financial Results

Record third quarter 2023 net sales of $4.5 million, an increase of approximately 128% over third quarter 2022 Company increases revenue guidance for full year 2023 to $15.0 million - $15.5 million Company to host a conference call and webcast today, November 8, 2023 at 4:30 PM EST ROCKAWAY, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company and wellness company, today announced third quarter 2023 financial results and prov

Yahoo | November 8, 2023

electroCore to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum

ROCKAWAY, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, is scheduled to attend the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum taking place at the Westin NY Grand Central on November 16, 2023. 1x1 Meetings electroCore will host 1x1 investor meetings on November 16, 2023. Please contact your Canaccord representative to schedul

Yahoo | November 7, 2023

Data Highlighting Non-invasive Vagus Nerve Stimulation (nVNS) for Treatment of Symptoms of Gastroparesis Presented at 2023 American College of Gastroenterology Annual Meeting

Clinical Trial suggests nVNS can reduce the use of rescue medications for exacerbations of nausea due to Gastroparesis or Functional Dyspepsia FIGURE 1 Primary Endpoint (n=35): Average number of nausea pills. Overall significance (Type 3 F test): p=0.0007 ROCKAWAY, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced top line data from an abstract being presented as an oral podium presentation at

Yahoo | October 24, 2023

electroCore Announces Two-Year Extension of gammaCore™ Device Listing in the NHS Supply Chain Catalogue

Extension maintains listing through March 17, 2026ROCKAWAY, N.J., Oct. 17, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial stage bioelectronic medicine and wellness company, announced today that gammaCore therapy will continue to be listed in the United Kingdom’s National Health Service (NHS) Supply Chain catalogue for an additional two years through March 17, 2026. The listing, which commenced on June 4, 2019, was scheduled to terminate on March 18, 2024. “We are delight

Yahoo | October 17, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!